Classification of antineoplastic drug-induced tissue damage: a Consensus of the Spanish Oncology Pharmacy Group.
Por:
Albert-Marí A, Gil-Lemus MªÁ, Conde-Estévez D, San José-Ruiz B, Jiménez-Pulido I, Esteban-Mensua MªJ, Cercós-Lletí AC and Díaz-Carrasco MªS
Publicada:
15 jun 2021
Ahead of Print:
15 jun 2021
Resumen:
OBJECTIVE: To reach at an expert consensus, using the Delphi method, for classifying the tissue-damaging potential of antineoplastic drugs, in order to facilitate the decision-making process in the event of extravasations. METHOD: The panel of expert evaluators was made up of seven pharmacists belonging to the working group on extravasations. Other member served as coordinator. The likelihood of tissue damage was reviewed on the basis of eight reference documents. Four categories of drugs were established: vesicant (V); high risk irritant (HRI); low risk irritant (LRI) and non-irritant (NI). Two rounds of surveys were performed. The drugs with an agreement of less than 70% after the two rounds were discussed non-anonymously by the group. For each of the rounds the following was analysed: median of the degree of consensus and the interquartile range (IQR25-75), degree of agreement by tissue damage category, and percentage of antineoplastics reaching a degree of consensus of over 85% and of 100%. Drugs whose classification differed in the various reference documents were assessed separately. SPSS v23.0 statistical software was used. RESULTS: Seventy-one antineoplastics were evaluated. In the first round, the median for degree of consensus was 100.0% (IQR25-75: 71.4- 100.0%). In the second round, the median was 100.0% (IQR25-75: 85.7- 100.0%). The percentage of antineoplastics with a consensus of 85.7% or above increased from 66.7% to 85.9% in the second round. For the 30 antineoplastics whose values differed in the reference documents, the degree of agreement increased from 71.4% (IQR25-75: 57.1-87.7%) to 100.0% (IQR25-75: 85.7-100.0%) in the second round. The percentage of antineoplastics with a consensus of 85.7% or above increased from 40.0% to 76.7%. Four antineoplastics had a degree of agreement of less than 70.0%. The final classification of drugs per category, was: 17 vesicants; 15 HRI; 13 LRI; and 26 NI. The final degree of consensus was 85.7% or above for 90.1% of antineoplastics, and 100.0% for 74.6% of the same. CONCLUSIONS: In this area of scarce evidence and high variability, the Delphi method allows for consensus in classifying tissue damage risk, thus making it easier to reach clinical decisions. In approximately 90% of the antineoplastics, the degree of consensus reached by the expert panel was 85% or above. In 74% of the antineoplastics, it was 100%. This provides solid ground for management decisions.
Filiaciones:
Albert-Marí A:
Department of Pharmacy, Hospital Universitario y Politécnico La Fe, Valencia. Spain..
Gil-Lemus MªÁ:
Department of Pharmacy, Hospital Universitario Cruces, Barakaldo (Vizcaya). Spain..
Conde-Estévez D:
Department of Pharmacy, Hospital del Mar, Barcelona. IMIM (Institut Hospital del Mar d'Investigacions Médiques), Barcelona. Spain..
San José-Ruiz B:
Department of Pharmacy, Hospital Universitario Cruces, Barakaldo (Vizcaya). Spain..
:
Department of Pharmacy, Hospital General Universitario de Elche (Alicante). Spain..
Esteban-Mensua MªJ:
Department of Pharmacy, Hospital Quirónsalud, Valencia. Spain..
:
Department of Pharmacy, Hospital Universitario Dr. Peset, Valencia. Spain..
Díaz-Carrasco MªS:
Department of Pharmacy, Hospital Clínico Universitario Virgen de la Arrixaca, Murcia. Spain..
Open Access
|